Quidel Co. (NASDAQ:QDEL) Director Kenneth F. Buechler sold 9,000 shares of Quidel stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $66.50, for a total transaction of $598,500.00. Following the sale, the director now owns 56,769 shares of the company’s stock, valued at approximately $3,775,138.50. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ:QDEL traded up $0.80 during trading hours on Friday, hitting $68.14. The company’s stock had a trading volume of 357,915 shares, compared to its average volume of 258,243. Quidel Co. has a 52 week low of $44.27 and a 52 week high of $77.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.79 and a current ratio of 1.21. The firm has a market cap of $2.63 billion, a P/E ratio of 24.16, a P/E/G ratio of 0.96 and a beta of 1.37.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings results on Wednesday, February 13th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.54 by $0.21. Quidel had a net margin of 14.20% and a return on equity of 31.73%. The business had revenue of $132.59 million during the quarter, compared to analyst estimates of $132.26 million. During the same quarter in the previous year, the business posted $0.56 EPS. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. On average, research analysts predict that Quidel Co. will post 2.77 EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Quidel by 16.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,353 shares of the company’s stock worth $115,000 after buying an additional 333 shares during the last quarter. United Services Automobile Association grew its position in shares of Quidel by 7.7% in the 4th quarter. United Services Automobile Association now owns 7,914 shares of the company’s stock worth $386,000 after buying an additional 566 shares during the last quarter. Legal & General Group Plc grew its position in shares of Quidel by 6.9% in the 4th quarter. Legal & General Group Plc now owns 13,708 shares of the company’s stock worth $670,000 after buying an additional 883 shares during the last quarter. Cutler Group LP purchased a new position in shares of Quidel in the 4th quarter worth approximately $43,000. Finally, Teachers Advisors LLC grew its position in shares of Quidel by 1.3% in the 3rd quarter. Teachers Advisors LLC now owns 71,353 shares of the company’s stock worth $4,650,000 after buying an additional 930 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on QDEL. ValuEngine lowered shares of Quidel from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Barclays restated a “buy” rating and issued a $74.00 price target on shares of Quidel in a report on Friday, February 15th. Zacks Investment Research lowered shares of Quidel from a “buy” rating to a “hold” rating in a report on Saturday, February 16th. Craig Hallum boosted their price target on shares of Quidel from $51.00 to $63.00 and gave the company a “hold” rating in a report on Thursday, February 14th. Finally, BidaskClub upgraded shares of Quidel from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Three analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $71.50.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Further Reading: Trading Ex-Dividend
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.